2022-2029 年口腔黏膜炎全球市场
市场调查报告书
商品编码
1140662

2022-2029 年口腔黏膜炎全球市场

Global Oral Mucositis Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

口腔黏膜炎市场规模预计在预测期间(2022-2029 年)将以 5.6% 的复合年增长率增长,高于 2021 年的 13.373 亿美元。

口腔粘膜炎 (OM) 是口腔和咽喉粘膜的溃疡或炎症。这是接受放射和化学疗法治疗头颈癌的患者的常见副作用和严重并发症。大约 40% 的化疗和所有放疗患者会发展为口腔粘膜炎。严重的 OM 并发症包括极度疼痛和炎症、感染风险增加、营养不良、脱水、说话困难和药物使用增加。如果不及时治疗,这些疮会导致危及生命的感染。口腔黏膜炎可通过多种测试诊断,包括活检和真菌测试。用于治疗 OM 的产品包括防腐漱口水、止痛剂、水溶性润滑剂、钝性漱口水和粘膜涂层。

市场动态

血液疾病的增加和技术进步是推动全球口腔粘膜炎市场的主要因素。

头颈癌发病率的增加预计将推动市场增长。

美国和欧洲的 HNC 年发病率分别约为 150,000 和 750,000。据说这些患者中约有 60-70% 会发展为严重的口腔粘膜炎 (SOM)。口腔黏膜炎是由细胞毒化学治疗剂对口腔黏膜的辐射效应和副作用引起的。美国国立卫生研究院估计,美国每年有超过 400,000 名患者被诊断出患有口腔粘膜炎。随着全球癌症患者数量的增加,口腔黏膜炎治疗药物的市场也在不断扩大。因此,口腔黏膜炎治疗药物的需求正在快速增长,预计将在预测期内推动市场增长。

此外,越来越多的临床试验和合作策略的采用正在加强口腔粘膜炎药物的研发。截至 2019 年 3 月,口腔黏膜炎管线包括 20 多种处于不同开发阶段的药物(此外还有 9 种非处方药)。 2020年6月,开发和商业化治疗罕见疾病药物的生物製药公司Soligenix, Inc.宣布SGX942(dusquetide)用于治疗头颈癌(HNC)患者的口腔黏膜炎(OM)。完成了 3 期 DOM-INNATE 试验的患者登记。註册现已完成,预计将在 2020 年第四季度获得一线结果。

口腔黏膜炎新药开发的研究进展也有望在预测期内推动市场增长。例如,2020 年 5 月,亚利桑那大学药学院的研究人员决定将以前用于治疗非洲昏睡病的具有百年历史的药物苏拉明重新用于对抗口腔粘膜炎和糖尿病足溃疡。这一突破性的发展可以使成千上万的患者受益,他们目前的治疗对他们来说是部分有效的或痛苦的和侵入性的。

预计与口腔粘膜炎产品相关的严格审批将阻碍市场增长。

但是,以美国食品和药物管理局 (USFDA)、欧洲药品管理局 (EMA) 和美国国立卫生研究院 (NIH) 等监管机构授予和指定的形式,专利的颁发和长期严格的产品审批减缓了市场增长。

行业分析

全球口腔粘膜炎市场根据波特五力、监管和报销分析、价值链分析、定价分析、供应链分析、未满足的需求和流行病学等各种行业因素对市场进行了深入分析。

细分分析

预计致病部分将占全球口腔粘膜炎市场的最大市场份额。

原因将全球口腔粘膜炎市场分为化疗、放疗和造血干细胞移植。其中,化学疗法引起的口腔粘膜炎预计将占据很大的市场份额,因为化学疗法被广泛用作癌症的治疗方法。例如,根据美国卫生与公众服务部的数据,美国每年有超过 650,000 名癌症患者在肿瘤门诊接受化疗。口腔黏膜炎药物市场包括冷冻疗法、生长因子、抗氧化剂、抗炎剂、低水平激光疗法(LLLT)、漱口水、阻隔剂和涂层等多种药物配方和治疗方法。批准用于治疗口腔粘膜炎的药物包括 Kepivance、GelX、NeutraSal、Easy 和 Caphosol。 2020年5月4日,美国WorldMeds推出了GELX ORAL GEL,这是一种锌-牛磺酸生物活性屏障疗法,可缓解口腔黏膜炎相关的口腔疼痛。 GELX ORAL GEL 是一种生物活性治疗药物,可在口腔粘膜炎中建立有效的抗疼痛和炎症屏障。提供针对口腔疼痛的生物防御,并覆盖暴露的神经末梢和开放性口腔炎。 GELX 通过提高药物释放率和溶解度的聚乙烯□咯烷酮递送系统向粘膜环境提供一种生物活性的牛磺酸锌复合物,该复合物已知可破坏和减缓口腔粘膜炎的炎症週期。 SGX942 (Soligenix, Inc.)、MuGard (Daewoong Pharmaceutical Co.)、CVXL-0095、Nu-3、Brilacidin 等正在研发中,预计将在预测期内进一步推动口腔黏膜炎治疗市场。一项将 brilacidin 作为漱口水预防头颈癌患者严重口腔粘膜炎 (SOM) 的 2 期试验也达到了主要和次要终点,包括降低 SOM 的发生率。除了高未满足的需求外,brilacidin 的初始价格是唯一的O.M.预期。我们的基线估计是,美国和欧洲的 brilacidin 漱口水市场每年将价值约 6 亿美元至 12 亿美元。

区域分析

北美地区在全球口腔粘膜炎市场中占有最大的市场份额。

由于该地区慢性生活方式疾病的流行率不断上升,北美在市场上占据主导地位。它拥有最大的市场份额,主要是由于该国头颈癌的患病率上升。例如,根据美国临床肿瘤学会 (ASCO) 的数据,头颈癌约占美国所有癌症的 4%。 2019 年,预计将有 65,410 人患上头颈癌。

根据美国临床肿瘤学会 (ASCO) 2021 年的一份报告,美国约有 4% 的人将患有头颈癌,预计将有 66,630 人患头颈癌。预计美国的高癌症病例将推动市场增长。

口腔黏膜炎每年在美国影响超过 500,000 人,代表了一个新市场,其中未满足的医疗保健需求在很大程度上是一个长期存在的问题。根据美国疾病控制和预防中心的数据,美国每年约有 650,000 名癌症患者在门诊接受化疗,而共识是每年约有 500,000 名患者发生口腔粘膜炎。

此外,用于开发治疗这种疾病的新产品的巨额资金和投资预计将推动美国市场的增长。例如,2020 年 6 月,Soligenix, Inc. 宣布完成 SGX942 (Daclyde) 治疗头颈癌 (HNC) 患者口腔黏膜炎 (OM) 的 3 期 DOM-INNATE 试验的患者入组。

Galera Therapeutics, Inc. 宣布在 2b 期临床试验中使用 Galera 的主要产品候选严重口腔粘膜炎 (SOM) 的头颈癌患者的总体肿瘤病程 (GC4419) 进行了 2b 期临床试验,该试验已于 2020 年 2 月披露。

竞争格局

口腔粘膜炎市场竞争激烈,由几家主要参与者和新进入者组成。为市场增长做出贡献的主要参与者包括 EUSA Pharma Inc.、Daewoong Pharmaceutical Co.、Soligenix, Inc.、Sunstar Suisse SA、Swedish Orphan Biovitrum Ltd.、Amgen Inc、Bausch Health、EKR Therapeutics, Inc. 包括 Access Pharmaceuticals, Inc、 Eisai Inc、Innovation Pharmaceuticals、Moberg Pharma AB 等。

值得关注的主要公司

Yusa Pharma Inc.

概述 EUSA Pharma Inc. 是一家全球专业製药公司。该公司发现、製造和销售特种药品。该公司提供抗癌药物、癌症治疗支持、重症监护等。 EUSA Pharma 在全球销售其产品。 EUSA Pharma 的临床研发致力于改善我们产品的使用,以最大限度地提高癌症和罕见病患者的临床利益。该公司是爵士製药的子公司。

产品组合 Kafosol:批准用于治疗和预防口腔黏膜炎,这是癌症治疗(包括放疗和化疗)的副作用。含有高浓度的磷酸根离子和钙离子,可润滑口腔、舌头和口咽部的黏膜,有助于保持口腔健康。 Cafosol 可作为安瓿或分散液使用。

我的实验室 (TM) 9V

全球口腔粘膜炎市场报告提供了对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第 1 章全球口腔黏膜炎市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章全球口腔黏膜炎市场 - 市场定义和概述

第 3 章全球口腔黏膜炎市场 - 执行摘要

  • 按原因划分的市场细分
  • 按处理方法划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章全球口腔粘膜炎市场 - 市场动态

  • 市场影响因素
    • 驱动程序
      • 头颈癌发病率增加
      • 增加研发投入
      • 在研药物增加
    • 限制因素
      • 可供选择的治疗方法
    • 商机
    • 影响分析

第 5 章全球口腔黏膜炎市场 - 行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 未满足的需求

第 6 章全球口腔黏膜炎市场 - 按原因

  • 化疗
  • 放射治疗
  • 造血干细胞移植

第 7 章全球口腔黏膜炎市场 - 按治疗方式

  • 漱口水
  • 成长因子
  • 低强度激光治疗 (LLLT)
  • 冷冻疗法
  • 其他

第 8 章全球口腔黏膜炎市场 - 按最终用户分类

  • 医院
  • 牙科诊所
  • 肿瘤中心
  • 研究所
  • 其他

第 9 章全球口腔黏膜炎市场 - 按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章全球口腔粘膜炎市场 - 竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 11 章全球口腔黏膜炎市场 - 公司简介

  • 大雄製药
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • EUSA Pharma Inc.
  • Soligenix, Inc.
  • Sunstar Suisse SA
  • Swedish Orphan Biovitrum Ltd.
  • Amgen Inc.
  • Bausch Health
  • EKR Therapeutics, Inc.
  • Access Pharmaceuticals, Inc.
  • Eisai Inc.
  • BioAlliance Pharma SA.
  • Camurus AB
  • Moberg Pharma AB

第 12 章全球口腔黏膜炎市场 - 主要考虑因素

第 13 章全球口腔黏膜炎市场-主要考虑因素全球口腔黏膜炎市场-DataM

简介目录
Product Code: DMPH2587

Market Overview

The Oral Mucositis Market size was valued at US$ 1,337.30 million in 2021 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Oral Mucositis (OM) is ulceration and inflammation of the mucosal membranes in the mouth and throat. It is a common side effect and serious complication for patients receiving radiation and chemotherapy with head and neck cancer treatments. About 40% of chemotherapy and all radiation patients develop oral mucositis. Serious OM complications include intolerable pain and inflammation, increased risk of infections, malnutrition, dehydration, difficulty speaking, and increased use of narcotics. If left untreated, these sores can lead to life-threatening infections. Oral mucositis is diagnosed through various tests, including biopsy and fungal testing. Antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses, and mucosal coating agents are some of the products used to treat OM.

Market Dynamics

Increase in hematological disorders and technological advancements are the major factors driving the global Oral Mucositis market.

Rising incidences of head and neck cancer are expected to drive market growth.

The annual incidence of HNC in the U.S. and Europe is approximately 150,000 and 750,000 cases globally. Approximately 60 to 70% of these patients will develop Severe Oral Mucositis (SOM). The side-effects of radiation effects and cytotoxic chemotherapy agents on oral mucosa lead to oral mucositis. As per the National Institutes of Health estimates, over 400,000 patients are diagnosed with oral mucositis annually in the United States. With the increasing prevalence of cancer patients globally, the market for oral mucositis therapeutics is also growing. Hence, the demand for oral mucositis treatment is rapidly growing, which is expected to drive market growth over the forecast period.

Besides, increasing clinical trials and the adoption of collaboration strategies are enhancing the oral mucositis therapeutics pipeline. As of March 2019, the oral mucositis therapeutics pipeline comprised more than twenty drugs (in addition to nine marketed drugs) in different development stages. In June 2020, Soligenix, Inc., a biopharmaceutical company developing and commercializing products to treat rare diseases, has completed patient enrollment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) for the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients. With the enrollment completed, top-line results are expected in the fourth quarter of 2020.

Growing research to develop new drugs for oral mucositis is also expected to boost market growth during the forecast period. For instance, in May 2020, researchers at the University of Arizona College of Pharmacy have reformulated Suramin, a 100-yearold drug previously used to treat African sleeping sickness, to fight oral mucositis and diabetic foot ulcers. This breakthrough development can benefit thousands of patients whose current healing options are either partially effective or painful and invasive.

Stringent approvals associated with oral mucositis products is expected to hamper the market growth.

However, the issuance of patents and long stringent approvals for products in the form of grants and designations from regulatory bodies, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH), among others is a slowing down the market growth.

Industry Analysis

The global oral mucositis market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory & reimbursement analysis, value chain analysis, pricing analysis, supply chain analysis, unmet needs, epidemiology etc.

Segment Analysis

Cause segment is expected to hold the largest market share in global oral mucositis market

Its cause segments the global oral mucositis market into chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Among these, the oral mucositis caused by the chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For instance, as per the U.S. Department of Health & Human Services, every year, more than 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the U.S. The oral mucositis therapeutics market includes several kinds of drug formulations and treatments such as cryotherapy, growth factors, antioxidants, anti-inflammatory agents, low-level laser therapy (LLLT), mouthwashes, barriers, and coating agents. Some of the approved drugs for oral mucositis treatment include Kepivance, GelX, NeutraSal, Easy, and Caphosol. On May 4th, 2020, the U.S. WorldMeds, launched GELX ORAL GEL, a Zinc-Taurine bioactive barrier therapy for relief from oral pain associated with oral mucositis. GELX ORAL GEL is a bioactive therapy that can build an effective barrier against oral mucositis's pain and inflammation. It biomechanically protects against intraoral pain, coating exposed nerve endings and open sores. Through a polyvinylpyrrolidone delivery system, which can improve the release rate and solubility of drugs, GELX supplies the mucosal environment with a bioactive Zinc-Taurine Complex known to hinder and delay the inflammatory cycle of oral mucositis. SGX942 (Soligenix, Inc.), MuGard (Daewoong Pharmaceutical Co.), CVXL-0095, Nu-3, Brilacidin, among others, are in the pipeline, which is expected to further drive the oral mucositis therapeutics market over the forecast period. Also, A phase 2 trial of Brilacidin, as an oral rinse for preventing Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer (HNC), met its primary and secondary endpoints, including reducing the incidence of SOM. The price for Brilacidin is anticipated at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other O.M. drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on the company's estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion.

Geographical Analysis

North America region holds the largest market share in the global oral mucositis market

North America is dominating the market due to increased prevalence of chronic lifestyle related diseases in the region. It accounts for the largest market share and is mainly attributed to the increasing prevalence of head and neck cancer in the country. For instance, according to the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers in the US. In 2019, an estimated 65,410 people will develop head and neck cancer.

According to the American Society of Clinical Oncology (ASCO)'s 2021 report, approximately 4% of individuals suffered from head and neck cancer in the U.S. and an estimate of 66,630 people were expected to develop head and neck cancer. High cases of cancer in the US is expected to drive market growth.

Oral mucositis affects over half a million people in the United States each year, and it provides a new market in which unmet health care needs are primarily intrinsically a long-standing problem. According to the Centers for Disease Control and Prevention, around 650,000 cancer patients get chemotherapy in an outpatient environment in the United States each year, and approximately 500,000 cases of oral mucositis occur in the United States each year, according to a consensus.

Moreover, huge funding and investments for the development of new products to treat the condition is expected to drive the market growth in the United States. Soligenix, Inc., for instance, announced in June 2020 that patient enrollment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in patients with head and neck cancer (HNC) had been completed.

Galera Therapeutics, Inc. disclosed full tumour outcomes of patients with head and neck cancer treated with avasopasem manganese (GC4419), which is Galera's primary product candidate for severe oral mucositis (SOM) that was in a Phase 2b clinical trial, in February 2020.

Competitive Landscape

The oral mucositis market is highly competitive and consists of several major players and new players in the market. Some of the key players which are contributing to the growth of the market are EUSA Pharma Inc., Daewoong Pharmaceutical Co., Soligenix, Inc., Sunstar Suisse SA, Swedish Orphan Biovitrum Ltd., Amgen Inc., Bausch Health, EKR Therapeutics, Inc., Access Pharmaceuticals, Inc., Eisai Inc., Innovation Pharmaceuticals, Moberg Pharma AB, among others.

Key Companies to Watch

EUSA Pharma Inc:

Overview: EUSA Pharma Inc is a global speciality pharmaceutical company. The company creates, manufactures, and sells specialised pharmaceutical products. The company provides oncology drugs, oncology support, and critical care. EUSA Pharma sells its products all over the world. EUSA Pharma Clinical Research and Development is involved in improving the use of its products to maximize the clinical benefit for patients who have cancer or rare diseases. The company is a subsidiary of Jazz Pharmaceuticals.

Product Portfolio: Caphosol: It is approved for the treatment and prevention of oral mucositis, a side effect of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions, which lubricate the mucosa of the mouth, tongue, and oropharynx and aid in the preservation of the oral cavity's integrity. Caphosol is available in ampules or as a dispersible solution.

MyLab™9V

The global oral mucositis market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Global Oral Mucositis market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Oral Mucositis market - Market Definition and Overview

3. Global Oral Mucositis market - Executive Summary

  • 3.1. Market Snippet by Cause
  • 3.2. Market snippet by Treatment
  • 3.3. Market snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Oral Mucositis market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of head & neck cancer
      • 4.1.1.2. Rising R&D investments
      • 4.1.1.3. Growing number of pipeline drugs
      • 4.1.1.4. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Availability of alternative treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Oral Mucositis market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs

6. Global Oral Mucositis market - By Cause

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
  • 6.3. Market Attractiveness Index, By Cause Segment
    • 6.3.1. Chemotherapy*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Radiotherapy
    • 6.3.3. Hematopoietic Stem Cell Transplantation

7. Global Oral Mucositis market - By Treatment

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 7.3. Market Attractiveness Index, By Treatment Segment
    • 7.3.1. Mouth Wash*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Growth Factors
    • 7.3.3. Low-level laser therapy (LLLT)
    • 7.3.4. Cryotherapy
    • 7.3.5. Others

8. Global Oral Mucositis market - By End-Users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
  • 8.3. Market Attractiveness Index, By End-Users Segment
    • 8.3.1. Hospitals*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Dental Clinics
    • 8.3.3. Oncology Centers
    • 8.3.4. Research Institutes
    • 8.3.5. Others

9. Global Oral Mucositis market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Global Oral Mucositis market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Oral Mucositis market- Company Profiles

  • 11.1. Daewoong Pharmaceutical Co.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. EUSA Pharma Inc.
  • 11.3. Soligenix, Inc.
  • 11.4. Sunstar Suisse SA
  • 11.5. Swedish Orphan Biovitrum Ltd.
  • 11.6. Amgen Inc.
  • 11.7. Bausch Health
  • 11.8. EKR Therapeutics, Inc.
  • 11.9. Access Pharmaceuticals, Inc.
  • 11.10. Eisai Inc.
  • 11.11. BioAlliance Pharma SA.
  • 11.12. Camurus AB
  • 11.13. Moberg Pharma AB

LIST NOT EXHAUSTIVE

12. Global Oral Mucositis market - Premium Insights

13. Global Oral Mucositis market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us